Skip to main content
. Author manuscript; available in PMC: 2020 Mar 5.
Published in final edited form as: Circulation. 2019 Mar 5;139(10):1275–1284. doi: 10.1161/CIRCULATIONAHA.118.036675

Table 1.

Participant Characteristics, by Sleep Apnea Severity Category (n=664)

Characteristics Total (n=664) REI4% <15 (n=493) REI4% 215 (n=171) P Value
Age (y), mean±SD 64.9±10.6 63.9±10.6 64.4±10.6 0.83
Male sex, n (%) 205 (30.9) 137 (27.8) 68 (39.8) <0.01
Education, n (%) 0.28
 < High school 64 (9.8) 51 (10.5) 13 (7.8)
 High school or graduate equivalency diploma 99 (15.2) 76 (15.7) 23 (13.8)
 Some college/training 154 (23.7) 106 (21.9) 48 (28.7)
 College degree 334 (51.3) 251 (51.9) 83 (49.7)
Body mass index, kg/m2
 Mean±SD 32.3±6.9 31.4±6.4 35.0±7.5 <0.01
 ≥30 387 (58.6) 267 (54.4) 120 (71.0) <0.01
Current/past smoker, n (%) 213 (34.2) 160 (34.7) 53 (32.7) 0.65
Alcohol use, yes vs no, n (%) 224 (34.3) 165 (33.9) 59 (35.5) 0.70
Depression symptoms, mean±SD 8.6±7.8 8.7±8.0 8.3±7.5 0.77
Perceived stress, mean±SD 11.2±7.0 11.3 + 7.2 11.0±6.5 0.73
Class of antihypertensive medications, n (%)
 α-Blockers 19 (2.9) 14 (2.9) 5 (3.0) 0.94
 β-Blockers 129 (19.7) 93 (19.1) 36 (21.4) 0.51
 Calcium-channel blockers 247 (37.6) 180 (36.9) 67 (39.6) 0.52
 Diuretics 333 (50.1) 243 (49.3) 90 (52.6) 0.45
 Angiotensin-converting enzyme inhibitors/ angiotensin II receptor blockers /renin inhibitors 336 (51.1) 242 (49.6) 94 (55.6) 0.17
 Peripheral vasodilators 10 (1.5) 6(1.2) 4 (2.4) 0.29
Number of antihypertensive medications, mean±SD 1.8±1.2 1.7±1.2 1.9±1.3 0.04
Diabetes mellitus, n (%) 187 (28.2) 132 (26.8) 55 (32.2) 0.18
Sleep duration <7 h, n (%) 376 (59.4) 277 (58.7) 99 (61.5) 0.53
Sleep efficiency ≥85%, n (%) 447 (70.6) 339 (71.8) 108 (67.1) 0.25
Percent time in hypoxemia, median ± interquartile range 0.4±2.1 0.2±0.9 3.4±6.0 <0.01
Hypertension category, n (%) 0.03
 Controlled 248 (37.3) 191 (38.7) 57 (33.3)
 Uncontrolled 320 (48.2) 241 (48.9) 79 (46.2)
 Resistant 96 (14.5) 61 (12.4) 35 (20.5)

REI indicates respiratory event index.